With no approved vaccine for Ebola outbreak, experts weigh testing a long shot
With no approved vaccine for the fast-growing Ebola outbreak in the DRC, experts weigh testing one with unknown protection.
STAT+: Trump’s CMS to allow skimpier plans on ACA exchanges
The new plans could leave patients on the hook for more of their health care costs.
STAT+: Why the WakeMed – Atrium Health hospital merger matters
Hospital execs worked in secret on the deal for two years.
STAT+: AstraZeneca picks up FDA approval for hypertension drug
The China question, FDA leadership shakeups, and other biotech news from The Readout
U.S. bans entry from Ebola-affected countries as American patient is identified
In response to an Ebola outbreak, the U.S. has banned entry for noncitizens who have been in the Democratic Republic of the Congo, Uganda, or South Sudan recently.
STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
The rejection may make the pharma firms remaining lawsuits more difficult.
STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
The question of whether to partner with Chinese firms — or see them as rivals — is tearing biotech apart, pitting peers and partners against one another
Texas is opening up a detransition clinic
Americans exposed to Ebola outbreak, Bill Cassidy's primary defeat, and more health news from Morning Rounds
Opinion: How to restore credibility to the CDC’s vaccine advisory committee
Jesse Goodman, former director of CBER and former FDA chief scientist, calls for five critical changes to restore trust in the Advisory Committee on Immunization Practices.
STAT+: The China question is tearing biotech apart
China's ascent is forcing U.S. biotech companies and investors to pick a side: Is it an ally or an existential threat?
Opinion: ‘Patient autonomy’ has nothing to do with childhood vaccine policies
Opinion: Vaccine policy it is not a matter of autonomy at all, because infants do not decline vaccination — their parents do.
STAT+: U.K. advocacy groups threaten court action over a key provision in the pharma trade deal with the U.S.
A pair of advocacy groups is threatening legal action unless the U.K. government revokes regulations at the heart of a new pharma trade agreement with the U.S.
In Ebola outbreak, a number of Americans in the Congo believed to have had exposure to suspected cases
A number of Americans who are in the Congo are believed to have had exposure to suspected cases in the country’s latest Ebola outbreak, sources have told STAT.
When should you get a mammogram? Conflicting advice makes it hard to know
When should you get a mammogram? Conflicting advice makes it hard to know.
STAT+: The hantavirus outbreak is prompting Covid flashbacks — including the conspiracies
The deadly outbreak of a rare strain of hantavirus on a cruise has generated echoes of the pandemic era, including conspiracy theories.
STAT+: Sen. Bill Cassidy loses primary as race heads to run-off in win for Trump
Key health lawmaker Sen. Bill Cassidy will lose his seat, as Louisiana’s Senate primary heads for a runoff between state treasurer John Fleming and Trump-backed Rep. Julia Letlow.
WHO declares Ebola outbreak an international public health emergency
The WHO said an Ebola outbreak first seen in the Democratic Republic of the Congo was an international public health emergency, underscoring the world's concerns.
Trump blasts ‘disloyal’ Sen. Cassidy while pushing challenger in Louisiana Republican primary
Bill Cassidy, leader of the Senate committee that oversees health policy, is fighting for his political life in Louisiana's Republican primary on Saturday.
Opinion: Marty Makary misunderstood something fundamental about the FDA
“The norm-shattering masks a more fundamental misunderstanding of how administrative power can bring about lasting change,” writes Joshua Sharfstein.
Opinion: The cloudy truth about ‘blue zones’
“There's been interest in longevity, promoting it, for millennia. But this 25-year campaign really brought it to the forefront,” Eric Topol says of blue zones.
